-+ 0.00%
-+ 0.00%
-+ 0.00%

Biohaven (BHVN) Could Be 67% Undervalued After Graves Data And Ono Deal

Simply Wall St·11/16/2026 03:25:02
Listen to the news

Biohaven (BHVN) is back in focus after using the 2026 American Thyroid Association meeting to showcase new Graves' disease data, highlight international Phase 3 enrollment for BHV-1300, and announce a licensing deal with Ono Pharmaceutical across several Asian markets.

Recent trading paints a mixed picture for Biohaven. The share price has eased over the past week, with a 7 day share price return of 4.56% and a 1 day move lower. However, the 30 day share price return of 28.20% and year to date share price return of 27.49% suggest momentum is rebuilding after earlier setbacks, while the 66.51% 1 year total shareholder return contrasts with a 54.07% decline in the 3 year total shareholder return as the market reassesses both growth potential and risk around the expanding autoimmune pipeline and the Ono Pharmaceutical deal.

Scan other autoimmune-focused opportunities that are moving on fresh data and partnerships with a hand-picked set of 36 healthcare AI stocks that rhyme with the Biohaven story.

After a sharp 30 day rebound and a much tougher three year record, Biohaven now sits at a fork in the road. Is most of the rerating already in the rear-view mirror, or is the bigger upside still ahead as valuation catches up to the pipeline and Ono deal economics?

Most Popular Narrative: 67% Undervalued

Biohaven last closed at $13.82, while the bullish analyst Narrative on Simply Wall St anchors on a fair value of $42.29 that leans on optimistic trial outcomes and licensing economics.

The pivotal Phase 3 trial of BHV-1300 in Graves’ disease, as a first MoDE extracellular protein degrader targeting pathogenic IgG1 TSH receptor autoantibodies, creates a potential new autoimmune revenue stream that is largely separate from epilepsy and could improve earnings diversification if successful.

See why 0 investors see Biohaven as 67% undervalued.

Result: Fair Value of $42.29 (UNDERVALUED)

Still, the bullish Biohaven story leans heavily on successful late stage epilepsy and Graves’ disease trials, while ongoing cash burn and potential dilution remain front of mind.

Find out about the key risks to this Biohaven narrative.

Next Steps

Sentiment around Biohaven is split, with real excitement about the upside potential and clear concern about what could go wrong if things misfire. Act while the data is fresh and weigh both sides by digging into the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond Biohaven?

If Biohaven has sharpened your focus on where risk and reward really meet, do not stop with a single ticker when plenty of other opportunities are lining up.